VYOME HOLDINGS, INC. Cost of Revenue
VYOME HOLDINGS, INC. (HIND) reported Cost of Revenue of $69.88 thousand for the 6-month period ending 2025-06-30, per its 8-K filed 2025-09-02.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2025-09-02
- VYOME HOLDINGS, INC. cost of revenue for the quarter ending 2018-03-31 was $769.00K, a 6.56% decline year-over-year.
- VYOME HOLDINGS, INC. cost of revenue for the quarter ending 2017-12-31 was $1.70M, a 95.41% increase year-over-year.
- VYOME HOLDINGS, INC. cost of revenue for the quarter ending 2017-09-30 was $1.31M, a 104.04% increase year-over-year.
- VYOME HOLDINGS, INC. cost of revenue for the quarter ending 2017-06-30 was $990.00K, a 47.32% increase year-over-year.
- VYOME HOLDINGS, INC. cost of revenue for fiscal 2019 was $2.95M, a 45.60% decline from fiscal 2018.
- VYOME HOLDINGS, INC. cost of revenue for fiscal 2018 was $5.42M, a 12.30% increase from fiscal 2017.
- VYOME HOLDINGS, INC. cost of revenue for fiscal 2017 was $4.83M, a 71.91% increase from fiscal 2016.
- VYOME HOLDINGS, INC. cost of revenue for fiscal 2016 was $2.81M, a 12.23% increase from fiscal 2015.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2025-06-30 | $69.88K 8-K · filed 2025-09-02 | |||
| 2024-06-30 | $15.87K 8-K · filed 2025-09-02 | |||
| 2019-12-31 | $2.95M 10-K · filed 2020-02-27 | |||
| 2018-12-31 | $5.42M 10-K · filed 2020-02-27 | |||
| 2018-03-31 | $769.00K 10-Q · filed 2018-05-10 | $2.47M derived: sum of 2 quarters · filed 2019-02-22 | $3.79M derived: sum of 3 quarters · filed 2019-02-22 | $4.78M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $3.02M derived: sum of 2 quarters · filed 2019-02-22 | $4.01M derived: sum of 3 quarters · filed 2019-02-22 | $4.83M 10-K · filed 2019-02-22 |
| 2017-09-30 | $1.31M 10-Q · filed 2017-11-03 | $2.30M derived: sum of 2 quarters · filed 2017-11-03 | $3.13M 10-Q · filed 2017-11-03 | $4.00M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-06-30 | $990.00K 10-Q · filed 2017-08-02 | $1.81M 10-Q · filed 2017-08-02 | $2.68M derived: sum of 3 quarters · filed 2018-05-10 | $3.33M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | $823.00K 10-Q · filed 2018-05-10 | $1.69M derived: sum of 2 quarters · filed 2018-05-10 | $2.34M derived: sum of 3 quarters · filed 2018-05-10 | $3.01M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $871.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $1.51M derived: sum of 2 quarters · filed 2018-03-05 | $2.19M derived: sum of 3 quarters · filed 2018-03-05 | $2.81M 10-K · filed 2018-03-05 |
| 2016-09-30 | $644.00K 10-Q · filed 2017-11-03 | $1.32M derived: sum of 2 quarters · filed 2017-11-03 | $1.94M 10-Q · filed 2017-11-03 | $2.59M derived: sum of 4 quarters · filed 2018-03-05 |
| 2016-06-30 | $672.00K 10-Q · filed 2017-08-02 | $1.29M 10-Q · filed 2017-08-02 | $1.95M derived: sum of 3 quarters · filed 2018-03-05 | $2.59M derived: sum of 4 quarters · filed 2018-03-05 |
| 2016-03-31 | $622.00K 10-Q · filed 2017-05-10 | $1.28M derived: sum of 2 quarters · filed 2018-03-05 | $1.92M derived: sum of 3 quarters · filed 2018-03-05 | |
| 2015-12-31 | $654.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $1.30M derived: sum of 2 quarters · filed 2018-03-05 | $2.50M 10-K · filed 2018-03-05 | |
| 2015-09-30 | $644.00K 10-Q · filed 2016-11-10 | $1.85M 10-Q · filed 2016-11-10 | ||
| 2014-12-31 | $2.91M 10-K · filed 2017-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |